未登录

Z

Zhichao Wang

Shanghai Jiao Tong University School of Medicine

H指数:18

被引数:1,269

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Consensus recommendations for neurofibromatosis type 1 management in Asia Pacific

亚太地区神经纤维瘤病1型管理共识建议

IF4.1

2026-10-010

OAAI

Mai-wei-yang-fei decoction protects against pulmonary fibrosis by reducing telomere shortening and inhibiting AECII senescence via FBW7/ TPP1 regulation

麦味养肺汤通过减少端粒缩短和抑制AECII衰老来对抗肺纤维化，其机制涉及FBW7/TPP1的调控。

IF8.3

2025-06-010

PRE

Renaming low-grade MPNST: look before we leap

低级别MPNST的重命名：三思而后行

IF13.4

2025-05-010

OA

Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: Advancing insights into tumor development

1型神经纤维瘤病相关神经系统肿瘤的新兴机制和治疗潜力: 推进对肿瘤发展的见解

NEURO-ONCOLOGY ADVANCES

IF4.1

2025-02-160

OAAI

Epidemiologic and survival analysis of malignant peripheral nerve sheath tumors: a retrospective cohort study

INTERNATIONAL JOURNAL OF SURGERY

IF10.1

2024-12-010

OAAI

Selumetinib for plexiform neurofibroma: advances and ongoing challenges

IF13.4

2024-10-030

PRE

Reduced PTPRS expression promotes epithelial-mesenchymal transition of Schwann cells in NF1-related plexiform neurofibromas

IF10.1

2024-09-010

OA

Genotype-phenotype correlations and treatment innovation of neurofibromatosis type 1 (NF1): Current understanding and perspective

CHINESE MEDICAL JOURNAL

IF7.3

2024-06-250

OAAI

Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study

CLINICAL AND TRANSLATIONAL MEDICINE

IF6.8

2024-03-083

OAAI

Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis

IF12

2024-02-252

PRE

Molecular mechanism of quercetin in treating RA-ILD based on network pharmacology, molecular docking, and experimental validation

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

IF3.1

2023-10-250

PRE

FOXM1 promotes neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor progression in a NUF2-dependent manner

CANCER GENE THERAPY

IF5

2023-07-241

PRE

LARP4B gene mutation is involved in the development of neurofibroma

CLINICAL AND EXPERIMENTAL DERMATOLOGY

IF2.8

2022-12-270

OA

Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours

JOURNAL OF PATHOLOGY CLINICAL RESEARCH

IF3.7

2022-12-199

OAAI

Role of nerves in neurofibromatosis type 1-related nervous system tumors

CELLULAR ONCOLOGY

IF4.8

2022-11-033

PRE

Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis

曲美替尼治疗1型神经纤维瘤病相关丛状神经纤维瘤和低级别胶质瘤的有效性和安全性: 系统评价和Meta分析

PHARMACEUTICALS

IF4.8

2022-07-3113

OAAI

Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response

FRONTIERS IN ONCOLOGY

IF3.3

2022-07-074

OAAI

Ubiquitin-binding domain in ABIN1 is critical for regulating cell death and inflammation during development

CELL DEATH AND DIFFERENTIATION

IF15.4

2022-04-1611

OA

Establishment and characterization of an immortalized human giant congenital melanocytic nevi cell line

PIGMENT CELL & MELANOMA RESEARCH

IF2.6

2022-03-072

PRE

Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK/Extracellular SignaleRegulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I

JOURNAL OF INVESTIGATIVE DERMATOLOGY

IF5.7

2022-03-017

OAAI